RT Journal Article
SR Electronic
T1 Derivation and validation of the subscales of the severe asthma questionnaire
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP PA1095
DO 10.1183/13993003.congress-2021.PA1095
VO 58
IS suppl 65
A1 Rupert Jones
A1 Michael Hyland
A1 Lanario Joseph
A1 Matthew Masoli
A1 Adel Mansur
A1 Andrew Menzies-Gow
A1 Stephen Fowler
A1 James Dodd
YR 2021
UL http://erj.ersjournals.com/content/58/suppl_65/PA1095.abstract
AB Background: The Severe Asthma Questionnaire (SAQ) is a health related quality of life questionnaire validated for use in severe asthma. It comprises 16 items yielding a mean SAQ Total score and an additional visual analogue scale of Global rating.Aims: To derive and validate clinically relevant subscales using exploratory factor analysis (EFA).Methods: The SAQ was completed by patients attending 6 UK severe asthma centres, along with other questionnaires and clinical data were included in the analysis. EFA using principal axis factoring and promax rotation was used to achieve best fit to data.Results: 460 patients provided data, 65% women, mean age 51 (16-83) yrs. A three factor solution achieved best fit and the 16 SAQ items formed three distinct but inter-correlated groups of items which were consistent with item content. The groups of items assessed impact of severe asthma on various life activities (My Life), emotions (My Mind) and of extra-pulmonary symptoms and side effects (My Body). The subscales showed differing associations with clinically relevant variables (lung function and mood).Conclusions: The 16 items of the SAQ can be scored as a single overall score or as subscales reflecting three different constructs that people with severe asthma use when making judgements about their lives. The subscale ‘My Life’ assesses the impact on daily and family life, ‘My Mind’ assesses the emotional impact and ‘My Body’ extrapulmonary symptoms. The MCID of the subscales is being evaluated currently.FootnotesCite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA1095.This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).